Abstract: This invention relates to a proteoglycan G 009 possessed of antitumoral and immunostimulating effects, and separated from the cultured Ganoderma lucidum (KFCC-10709), containing:.beta.-glucose, .alpha.-glucose, galactose, .alpha.-mannose and fructose as saccharide components, and glycine, alanine, histidine, arginine, valine, aspartic acid, threonine, isoleucine, serine, leucine, glutamic acid, tyrocine, proline, phenylalanine and methionine as protein components.
Type:
Grant
Filed:
August 4, 1993
Date of Patent:
December 17, 1996
Assignee:
Il-Yang Pharmaceutical Co., Ltd.
Inventors:
Kwon H. Lee, Hoon Chung, Choon W. Lee, Chun H. Chung
Abstract: The invention provides a method of treating a viral infection in a mammal comprising administering an effective amount of modified C-reactive protein (CRP) to the mammal. In particular, modified-CRP has been found to be effective and safe for treating retroviral infections, including human immunodeficiency virus 1. The invention also provides a method of neutralizing a virus comprising contacting the virus with modified-CRP. In particular, modified-CRP can be used to neutralize viruses in blood which is to be used for transfusions by adding the modified-CRP to the blood prior to the transfusion.
Abstract: Tibial growth potentiating peptides which are unreactive in an enzyme immunoassay for human growth hormone have been isolated from human pituitary glands and human plasma. The peptides have a molecular weight of less than 10,000 daltons.
Type:
Grant
Filed:
October 12, 1994
Date of Patent:
November 19, 1996
Assignee:
The Penn State Research Foundation
Inventors:
Wesley C. Hymer, Krishnaswamy Krishnan, Wayne Lanham
Abstract: The present invention relates to the use of a pharmaceutic composition containing urodilatin as an active substance and optionally pharmaceutically usual diluents, excipients, fillers or adjuvants for treating pulmonary and/or bronchial diseases.
Abstract: A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.
Type:
Grant
Filed:
May 22, 1995
Date of Patent:
October 15, 1996
Assignees:
Genentech, Inc., Washington University
Inventors:
Ross G. Clark, Neil Gesundheit, Marc R. Hammerman, Steven B. Miller
Abstract: The invention relates to stabilized solutions with F VIII coagulation activity, to a process for the preparation thereof and to the use thereof.
Abstract: The invention concerns pharmaceutical compositions for use in the treatment of gastric disorders associated with Helicobacter pylori comprising a bacteriocin antimicrobial agent optionally coadministered with a release-delaying substance.
Abstract: The invention relates to a method for producing isolating and purifying trophoblast interferon proteins such as .beta.-interferons, .alpha..sub.I -interferon proteins, .alpha..sub.II -interferon proteins, and .gamma.-interferon proteins, and to a method of using the interferon proteins, e.g. for inhibiting tumoral growth or metastatic processes, for preventing graft-versus-host reaction, against leukemia, against viral activity, and against infection of the placenta; as well as antibodies against the interferon proteins.
Type:
Grant
Filed:
December 6, 1991
Date of Patent:
July 30, 1996
Assignee:
Landsforeningen til Kraeftens Bekaemplse
Inventors:
Peter Ebbesen, George Aboagye-Mathiesen, Ferenc D. Toth
Abstract: This invention includes a method of treating subjects with immunologic and hematologic disorders, such as immune deficiencies and anemias characterized by deficient total hemoglobin. The treatment includes administering to the subject insulin-like growth factor binding protein-3 (IGFBP-3), alone or in a complex including an insulin-like growth factor (IGF), in an amount sufficient to improve the immunologic and/or hematologic disorder, for example, increasing the level of total hemoglobin or improving immune deficiencies, such as occur post-chemotherapy. Another aspect of the invention includes administering IGFBP-3 alone to treat IGF-driven lymphoproliferative conditions, such as leukemias, inflammatory skin diseases, and nasal polyps.
Type:
Grant
Filed:
February 23, 1995
Date of Patent:
June 18, 1996
Assignee:
Celtrix Pharmaceuticals
Inventors:
Joseph A. Carlino, Howard R. Higley, Christopher A. Maack
Abstract: An imidoester, cross-linked hemoglobin composition useful in the transport of oxygen to living cells and being essentially free of any impurities, a P50 of at least 13mm Hg and predominantly in tetraruer form. Preferably, the cross-linked hemoglobin composition has a predominant molecular weight of at least 64,000. The purified and cross-linked hemoglobin has improved cross-link stability to autoxidation and can be used as a blood substitute for mammals or as an oxygen transport fluid.
Type:
Grant
Filed:
June 15, 1994
Date of Patent:
May 28, 1996
Assignee:
The Upjohn Company
Inventors:
Robert L. Garlick, Joseph P. Martin, Jr., Stephen B. Lyle
Abstract: The invention relates, as new compounds, to derivatives of tetrameric human haemoglobin corresponding to the covalent coupling of a haemoglobin tetramer and a polycarboxy-substituted compound having at least 4 -COO.sup.- groups, the said polycarboxy-substituted compound effecting an internal crosslinking of the two dimers of haemoglobin and conferring thereon an affinity for oxygen which is compatible with an in vivo use of the conjugate when the natural allosteric effector of haemoglobin is not present. Among carboxy-substituted compounds, special mention is made of benzenehexacarboxylate and benzenetetracarboxylate.
Type:
Grant
Filed:
August 10, 1992
Date of Patent:
May 7, 1996
Assignee:
Pasteur Merieux Serums et Vaccins
Inventors:
Edith Dellacherie, Daniel Sacco, Michel Grandgeorge
Abstract: Peptides of the formulaR.sub.1 --HX.sub.1 DX.sub.2 IX.sub.3 Iwherein R.sub.1, X.sub.1, X.sub.2 and X.sub.3 are defined as in the specification having antihypertensive activity without vascoconstricting activity.
Abstract: A method for decreasing the concentration of free actin in the plasma of an animal is described which comprises the administration of native and modified actin-binding proteins, and especially the administration of native and modified actin-binding regions of gelsolin. Diagnostic methods for identifying animals in need of such treatment are also described.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
April 16, 1996
Assignee:
Brigham & Women's Hospital
Inventors:
Thomas P. Stossel, Stuart E. Lind, Paul A. Janmey
Abstract: A process for the long-term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long-term basis by treatment corresponding to that of the treatment for obesity.
Type:
Grant
Filed:
August 8, 1994
Date of Patent:
March 5, 1996
Assignee:
Louisiana State University and Agricultural and Mechanical College
Abstract: A process is provided for purifying Urogenital Sinus Derived Growth Inhibitory Factor (UGIF) from embryonic tissue which comprises chromatographing medium from cultures or culture-derived spheroids of embryonic tissue derived from the urogenital sinus by gel filtration chromatography. Further purification by reverse phase high pressure liquid chromatography is also demonstrated. The UGIF is obtained in 70-fold to 8000-fold purification over the conditioned medium. A UGIF composition of matter is also provided, as is a method for treating neoplasia with UGIF.
Abstract: A stimulator for bone formation containing human interleukin 4 or an analogue thereof as an active ingredient. This stimulator is useful for the prevention and treatment of, for example, osteoporosis, osteogenesis imperfecta, injured bone and abnormality of dental and the improvement of metabolic abnormality of bone.
Abstract: Administration of a corticotropin-releasing factor (or a salt or analog thereof) decreases the leakage of blood components into tissues produced by various adverse medical conditions. Thus, treatments with corticotropin-releasing factor are useful in systemic inflammatory conditions.
Type:
Grant
Filed:
April 19, 1994
Date of Patent:
January 30, 1996
Assignee:
The Regents of the University of California
Abstract: The present invention relates to the use of iGF-II or effective analogues thereof for the manufacture of a medicament for prevention or treatment of nutritional or gastrointestinal disorders and for promoting human or animal neonatal growth. It also relates to composition comprising exogenous human or animal IGF-II or effective analogues thereof in a therapeutically effective amount together with a pharmaceutically acceptable carrier or diluent or foodstuff, preferably in admixture with artificial or natural milk or colostrum. The invention may be applied both in man and in animals.
Abstract: This invention relates to new vasopressin and vasotocin derivatives of general formula I ##STR1## in which A stands for the radical Mca (=3-mercapto-3,3-cyclpentamethylenepropionyl radical) or for the radical Mpa (=3-mercaptopropionyl radical),B stands for the amino acid radicals D-Tyr, D-Tyr(Et), D-Phe, Tyr(OMe), D-lle, D-Trp, or the radical of a hydrophobic D-amino acid, andC stands for phenylalanine (Phe; vasopressin derivatives) or isoleucine (lle; vasotocin derivatives).They have a high activity toward the oxytocin and the V-vasopressin receptors and can be used for the production of pharmaceutical agents.
Type:
Grant
Filed:
December 20, 1993
Date of Patent:
November 28, 1995
Assignee:
Schering Aktiengesellschaft
Inventors:
Falk Fahrenholz, Walter Elger, Marianne Fahnrich, Kryzsztof Chwalisz
Abstract: The present invention relates to the use of analogs of thrombomodulin ("TM") that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to inhibit the direct procoagulant activities of thrombin, such as, for example, thrombin-mediated conversion of fibrinogen to fibrin. These analogs are useful in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed. Included are methods for increasing the circulating half life of the proteins.
Type:
Grant
Filed:
November 22, 1993
Date of Patent:
November 14, 1995
Assignee:
Schering Aktiengesellschaft
Inventors:
Charles B. Glaser, Michael J. Morser, David R. Light